Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Melaleuca alternifolia leaf refers to the leaves of the Australian native plant commonly known as tea tree. The essential oil derived from these leaves, known as tea tree oil, is obtained by steam distillation and is widely used in over-the-counter topical products for its antiseptic, anti-inflammatory, broad-spectrum antimicrobial, and antioxidant properties. The primary active component is terpinen-4-ol, which disrupts microbial cell membranes and inhibits inflammatory mediator production such as TNF-alpha and interleukins. It has been studied for use in conditions like acne vulgaris, athlete’s foot (tinea pedis), nail fungus (onychomycosis), seborrheic dermatitis, chronic gingivitis, MRSA colonization prevention/treatment, minor cuts/scrapes/burns protection against infection. Oral ingestion is contraindicated due to toxicity[1][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on melaleuca alternifolia leaf.